CL2023003068A1 - Compuestos, composiciones y métodos para el tratamiento de trastornos - Google Patents
Compuestos, composiciones y métodos para el tratamiento de trastornosInfo
- Publication number
- CL2023003068A1 CL2023003068A1 CL2023003068A CL2023003068A CL2023003068A1 CL 2023003068 A1 CL2023003068 A1 CL 2023003068A1 CL 2023003068 A CL2023003068 A CL 2023003068A CL 2023003068 A CL2023003068 A CL 2023003068A CL 2023003068 A1 CL2023003068 A1 CL 2023003068A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- methods
- compositions
- treating cancer
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175974P | 2021-04-16 | 2021-04-16 | |
| US202163281493P | 2021-11-19 | 2021-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003068A1 true CL2023003068A1 (es) | 2024-05-03 |
Family
ID=81580947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003068A CL2023003068A1 (es) | 2021-04-16 | 2023-10-13 | Compuestos, composiciones y métodos para el tratamiento de trastornos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240228482A1 (https=) |
| EP (1) | EP4323358A1 (https=) |
| JP (1) | JP2024514339A (https=) |
| KR (1) | KR20240037184A (https=) |
| AU (1) | AU2022256514A1 (https=) |
| BR (1) | BR112023021068A2 (https=) |
| CA (1) | CA3215395A1 (https=) |
| CL (1) | CL2023003068A1 (https=) |
| CO (1) | CO2023015484A2 (https=) |
| IL (1) | IL307732A (https=) |
| MX (1) | MX2023012245A (https=) |
| PE (1) | PE20240767A1 (https=) |
| TW (1) | TW202309023A (https=) |
| WO (1) | WO2022221704A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| US20250042896A1 (en) * | 2021-10-29 | 2025-02-06 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Polycyclic compound as cbl-b inhibitor |
| AU2022379959A1 (en) | 2021-11-05 | 2024-05-09 | Genentech, Inc. | Lactams as cbl-b inhibitors selective over c-cbl |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AU2023307165A1 (en) * | 2022-07-12 | 2025-02-06 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4558504A1 (en) * | 2022-07-18 | 2025-05-28 | Insilico Medicine IP Limited | Cbl-b inhibitors and methods of uses thereof |
| WO2024077236A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024077244A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024086730A1 (en) * | 2022-10-19 | 2024-04-25 | Hotspot Therapeutics, Inc. | Heterocyclic cbl-b inhibitors for the treatment of cancer |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4653436A1 (en) * | 2023-01-19 | 2025-11-26 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | Heterocyclic compounds, preparation method therefor and use thereof |
| CN120530105A (zh) * | 2023-01-20 | 2025-08-22 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| WO2024227436A1 (en) * | 2023-05-04 | 2024-11-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025067342A1 (zh) * | 2023-09-27 | 2025-04-03 | 北京望实智慧科技有限公司 | 用作Cbl-b抑制剂的化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740837A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel |
| MY150032A (en) * | 2007-07-19 | 2013-11-29 | Merck Sharp & Dohme | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2008317353B2 (en) * | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| CA3041650A1 (en) * | 2016-10-27 | 2018-05-03 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| WO2019131575A1 (ja) * | 2017-12-26 | 2019-07-04 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除剤 |
| CA3136348A1 (en) * | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| MX2021015675A (es) * | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| JP2020169215A (ja) * | 2020-07-15 | 2020-10-15 | 住友化学株式会社 | 複素環化合物を用いる有害節足動物防除方法 |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AU2023307165A1 (en) * | 2022-07-12 | 2025-02-06 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
-
2022
- 2022-04-15 AU AU2022256514A patent/AU2022256514A1/en active Pending
- 2022-04-15 EP EP22721591.0A patent/EP4323358A1/en active Pending
- 2022-04-15 IL IL307732A patent/IL307732A/en unknown
- 2022-04-15 TW TW111114558A patent/TW202309023A/zh unknown
- 2022-04-15 CA CA3215395A patent/CA3215395A1/en active Pending
- 2022-04-15 JP JP2023564025A patent/JP2024514339A/ja active Pending
- 2022-04-15 MX MX2023012245A patent/MX2023012245A/es unknown
- 2022-04-15 KR KR1020237039416A patent/KR20240037184A/ko active Pending
- 2022-04-15 BR BR112023021068A patent/BR112023021068A2/pt unknown
- 2022-04-15 PE PE2023002860A patent/PE20240767A1/es unknown
- 2022-04-15 US US18/286,966 patent/US20240228482A1/en active Pending
- 2022-04-15 WO PCT/US2022/025083 patent/WO2022221704A1/en not_active Ceased
-
2023
- 2023-10-13 CL CL2023003068A patent/CL2023003068A1/es unknown
- 2023-11-16 CO CONC2023/0015484A patent/CO2023015484A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022256514A1 (en) | 2023-10-19 |
| MX2023012245A (es) | 2024-03-11 |
| KR20240037184A (ko) | 2024-03-21 |
| WO2022221704A1 (en) | 2022-10-20 |
| CO2023015484A2 (es) | 2023-11-30 |
| JP2024514339A (ja) | 2024-04-01 |
| TW202309023A (zh) | 2023-03-01 |
| EP4323358A1 (en) | 2024-02-21 |
| BR112023021068A2 (pt) | 2024-01-23 |
| PE20240767A1 (es) | 2024-04-17 |
| US20240228482A1 (en) | 2024-07-11 |
| IL307732A (en) | 2023-12-01 |
| CA3215395A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| CL2022000922A1 (es) | Aminas bicíclicas como inhibidores de la cdk2. | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| MX2020010469A (es) | Inhibidores del atf6 y sus usos. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| MX2020009147A (es) | Moduladores de la expresion de irf4. | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| CL2024002371A1 (es) | Compuestos con estructura en t formada por al menos cuatro ciclos para tratamiento del cáncer | |
| PE20201349A1 (es) | Moduladores de la expresion de ezh2 | |
| CL2021000107A1 (es) | Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma | |
| CO2025016192A2 (es) | Moléculas y métodos de uso de estas | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| MX2022016179A (es) | Compuestos y metodos para tratar infecciones fungicas. | |
| MX2024005379A (es) | Agonista de tlr7 y combinaciones para el tratamiento del cancer. | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
| BR112022008365A2 (pt) | Inibidores de cd73 |